Virax Holdings granted Transgene an exclusive license to its Co-X-Gene™ technology patents. Transgene will use the platform to progess two of its immunotherapeutic products—TG 4010 currently in Phase IIb trials for non-small-cell-lung cancer and TG 4001, which has completed Phase II trials against human papilloma virus-associated pathologies.
The license applies specifically to the U.S. and Canada. Virax will receive an upfront license fee and will share in fees and milestone payments that Transgene may receive if it out-licenses either of these products. Virax could earn up to $12 million under the agreement—$9 million for TG4010 and $3 million for TG4001. Additionally, it will also gain royalties on net sales of the licensed products in North America.